Literature DB >> 19129071

The antitumor activity of meisoindigo against human colorectal cancer HT-29 cells in vitro and in vivo.

Zuo Mingxin1, Li Yan, Wang Hongbo, Zhou Jianhua, Li Hongyan, Liu He, Xin Hongqi, Zhang Sen, Chen Xiaoguang.   

Abstract

The study was conducted to examine the antitumor activity of meisoindigo on HT-29 cells in vitro and in vivo. The cytotoxicity of meisoindigo was evaluated by MTT assay. The related genes and proteins were inspected with RT-PCR and western blot assay respectively, and the effects of meisoindigo on the cell cycle were analyzed by flow cytometry. The efficacy of meisoindigo in vivo was evaluated in an HT-29 cell xenograft nude mice model. The results show that meisoindigo effectively inhibits HT-29 cell proliferation (IC(50) 4.3 mmol/L), arrests HT-29 cells in G2/ M phase and induces HT-29 cell apoptosis. The downstream genes and proteins of GSK-3beta(ser(9)) expression level decrease. Meisoindigo significantly inhibits the HT-29 xenograft tumors growth at the dose of 100 mg/kg. The mechanism of meisoindigo activity against HT-29 cells may be related to its inhibition of glycogen synthase kinase-3beta, GSK-3beta(ser(9)) phosphorylation in Wnt signaling pathway. These findings indicate the potential value of meisoindigo for the treatment of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19129071     DOI: 10.1179/joc.2008.20.6.728

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  The continuing search for antitumor agents from higher plants.

Authors:  Li Pan; Heebyung Chai; A Douglas Kinghorn
Journal:  Phytochem Lett       Date:  2010-03-12       Impact factor: 1.679

Review 2.  Discovery of new anticancer agents from higher plants.

Authors:  Li Pan; Hee-Byung Chai; Alan Douglas Kinghorn
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

3.  LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.

Authors:  Mingxin Zuo; Chenglong Li; Jiayuh Lin; Milind Javle
Journal:  Oncotarget       Date:  2015-05-10

4.  Pathway-Centric Structure-Based Multi-Target Compound Screening for Anti-Virulence Drug Repurposing.

Authors:  Li Xie; Lei Xie
Journal:  Int J Mol Sci       Date:  2019-07-17       Impact factor: 5.923

5.  Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway.

Authors:  Yingze Ye; Tong Jin; Xu Zhang; Zhi Zeng; Baixin Ye; Jinchen Wang; Yi Zhong; Xiaoxing Xiong; Lijuan Gu
Journal:  Front Cell Neurosci       Date:  2019-12-16       Impact factor: 5.505

6.  [The impact of meisoindigo on apoptosis and proliferation of SET2 cell line by JAK-STAT pathway].

Authors:  C L Lyu; J Q Liu; M Chen; B Chen; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-01-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.